Irwin Naturals Files Q3 2022 Financials

Written by Customer Service on December 5, 2022. Posted in Earnings Releases And Operating Results.

Successful Execution on Ketamine Clinic
Rollup Strategy and Cannabis Licensing to Accelerate Future Growth

LOS ANGELES, Dec. 05, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced the Company filed results for its third quarter of fiscal 2022, the period ended September 30, 2022 on www.sedar.com.

Sean Sand, CFO, stated, “Despite cost pressures continuing through the quarter, we were able to grow our Gross Margins by +4.8% over Q3 2021. The Gross Margin increase can be attributed to sales mix coupled with the early success of a targeted price increase across the market. In addition, we were still able to maintain positive Operating Profits despite the additions in the cost base to support the early phases of the Emergence and Licensing businesses.”

Mr. Sand continued, “Our balance remains strong, and have access to considerable working capital to fund our accelerated growth plans. To date we have closed or announced agreements to acquire entities or assets amounting to 18 clinics and anticipate several more closing as we exit 2022 and in the coming quarters. In addition, we are continuing our rollout of our licensing deals, which now sees us in six states and in Canada.”

Financial Summary

	Three months ended											Nine Months Ended
(in thousands)	September 30,						$			%		September 30,				$			%
Combined Statement of Profit	2022			2021			Change			Change		2022		2021		Change			Change
Non-CBD operating revenue	$	20,346		$	20,899		$	(553	)	-2.6	%	$	61,205	$	66,334	$	(5,129	)	-7.7	%
CBD operating revenue		1,679			2,774			(1,095	)	-39.5	%		5,221		8,067		(2,846	)	-35.3	%
Total Operating Revenue		22,024			23,673			(1,649	)	-7.0	%		66,427		74,401		(7,974	)	-10.7	%

Gross Profit		10,603			10,117			486		4.8	%		31,208		33,970		(2,762	)	-8.1	%

Income from Operations		622			1,232			(610	)	-49.5	%		3,653		8,170		(4,517	)	-55.3	%

Net Profit / (Loss)		(583	)		(1,466	)		883		60.2	%		1,109		5,226		(4,117	)	-78.8	%

	As of			As of			$			%
Statement of Financial Position	Sept 30, 2022			Dec 31, 2021			Change			Change
Total assets		71,527			47,219			24,308		51.5	%
Total liabilities		41,027			24,103			16,924		70.2	%

Klee Irwin, CEO, commented, “In Q3, Irwin Naturals moved close to becoming the world’s largest chain of dedicated psychedelic mental health clinics. In addition, we are rapidly on our way to doubling our profits from last year on an annualized basis based on potential acquisitions in the psychedelic mental. The mental healthcare industry is a 1.5 trillion dollar behemoth in desperate need of a disruptive sea change. With standard treatments having an average effectiveness of approximately 17%, the drastic improvements of results from psychedelic treatments is that sea change. We currently have no meaningful competitors in our rearview mirror and intend to be the world’s first chain of clinics in this sector to exceed 100 locations.”

Financial Highlights

The 7% decline in overall operating revenues were due largely to supply issues in the CBD segment, related to a reduction in supply at a key supplier. The decline, though still down from prior year, is recovering quarter over quarter. Production of CBD products has restarted at the Company’s manufacturer. Other factors impacting sales related to order timing and the loss of distribution of certain non-CBD mass market products.
Income from operations in Q3 2022 came in at $0.6 million, as compared to $1.2M million for the same period in the prior year. The reduction in income was driven primarily by the aforementioned decrease in business volume and startup costs related to Emergence by Irwin Naturals (ketamine clinics) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry).
The overall decrease in business volume paired with startup costs related to the Company’s initiatives in cannabis and the aforementioned startup costs, resulted in a decrease in Adjusted EBITDA¹ to $0.5 million.

	Three months ended											Nine months ended
(in thousands)	September 30,						$			%		September 30,					$			%
	2022			2021			Change			Change		2022			2021		Change			Change
Net Profit	$	(583	)	$	(1,466	)	$	883		60.2	%	$	1,109		$	5,226	$	(4,117	)	-78.8	%
Interest Expense		181			34			147		432.4	%		541			91		450		494.5	%
Income Tax Expense		1,024			162			862		532.1	%		2,003			351		1,652		470.7	%
Depreciation and Amortization		468			353			115		32.6	%		1,299			1,061		238		22.4	%
EBITDA	$	1,090		$	(917	)	$	2,007		218.9	%	$	4,952		$	6,729	$	(1,777	)	-26.4	%

Foreign Exchange (Gain) / Loss		(33	)		–			(33	)	100.0	%		(45	)		–		(45	)	100.0	%
Listing Expenses		–			2,502			(2,502	)	0.0	%		–			2,502		(2,502	)	0.0	%
Other Income		–			–			–		100.0	%		–			–		–		0.0	%
Adjusted EBITDA	$	1,057		$	1,585		$	(528	)	-33.3	%	$	4,907		$	9,231	$	(4,324	)	-46.8	%

¹EBITDA is a non IFRS metric that management believes provides a metric for rapid analysis of the underlying strength of the business. A reconciliation from IFRS to EBITDA is provided in the accompanying table above and at the end of this release.

Cash provided by operating activities by Irwin were $3.6 million and $14.6 million for the nine months ended September 30, 2022 and 2021, respectively. The decrease in operating cash flows is primarily due to lower operating revenue and temporary unfavourability to working capital led by the timing of payments to the Company’s primary product manufacturer couple with increased cash related to Emergence startup costs.

Operational Highlights & Subsequent Events

Irwin Naturals is executing on an aggressive expansion strategy into the high-growth cannabis and psychedelics sectors. The Company intends to leverage its household name brand status to drive an aggressive rollup of mental health clinics (the Company is focused on ketamine clinics, as this is currently the only FDA-approved and/or regulated psychedelic substance). Furthermore, the Company has begun executing on its brand licensing strategy throughout the US. To date, the Company has announced agreements to acquire entities or assets; or completed the acquisition of such entities or assets amounting to 17 clinics, as well as the signing of seven brand licensing deals that will see Irwin Naturals products enhanced with THC be offered in California, Colorado, New Mexico, Mississippi, Ohio, Michigan and Canada.

State	Clinic Acquisitions
Florida	Ketamine Health Centers (5 clinics) Florida Mind Health (3 clinics) Dura Medical (1 clinic)
Iowa	Midwest Ketafusion
New Hampshire	New England Ketamine
Mexico	Ketamine Health Centers
Vermont	Preventive Medicine
Georgia	Invictus Clinics (2 clinics)
Washington	Tri-Cities Infusion
Idaho	Ketamine Infusions of Idaho
Ohio	Happier You
Kentucky	Serenity Health

State	Brand License Recipients
California	The Hive Laboratory, LLC
Colorado	Larsen Group II, LLC
Ohio	BeneLeaves, Ltd
New Mexico	Assurance Laboratories, LLC
Canada	Entourage Health Corp.
Mississippi	Mockingbird Cannabis, LLC
Michigan	42 Degrees Processing, LLC

Business highlights and subsequent events

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years¹. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand². In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to Investors@IrwinNaturals.com.

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
investors@irwinnaturals.com

IR Information

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
investors@irwinnaturals.com

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA“) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License“). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA“). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

EBITDA and Adjusted EBITDA – Reconciliation

The Company defines EBITDA and Adjusted EBITDA as per the table below. It should be noted that these performance measures are not defined under IFRS and may not be comparable to similar measures used by other entities. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:

	Three months ended											Nine months ended
(in thousands)	September 30,						$			%		September 30,					$			%
	2022			2021			Change			Change		2022			2021		Change			Change
Net Profit	$	(583	)	$	(1,466	)	$	883		60.2	%	$	1,109		$	5,226	$	(4,117	)	-78.8	%
Interest Expense		181			34			147		432.4	%		541			91		450		494.5	%
Income Tax Expense		1,024			162			862		532.1	%		2,003			351		1,652		470.7	%
Depreciation and Amortization		468			353			115		32.6	%		1,299			1,061		238		22.4	%
EBITDA	$	1,090		$	(917	)	$	2,007		218.9	%	$	4,952		$	6,729	$	(1,777	)	-26.4	%

Foreign Exchange (Gain) / Loss		(33	)		–			(33	)	100.0	%		(45	)		–		(45	)	100.0	%
Listing Expenses		–			2,502			(2,502	)	0.0	%		–			2,502		(2,502	)	0.0	%
Other Income		–			–			–		100.0	%		–			–		–		0.0	%
Adjusted EBITDA	$	1,057		$	1,585		$	(528	)	-33.3	%	$	4,907		$	9,231	$	(4,324	)	-46.8	%

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Financial Position

		September 30,			December 31,
	Notes	2022			2021
ASSETS
Current Assets:
Cash		$	1,205		$	625
Other Financial Assets			–			1
Trade Receivables	15		14,236			16,394
Inventory	6		23,547			18,652
Prepaid Expenses and Other Current Assets	5		2,182			1,469
Total Current Assets			41,170			37,141

Non-Current Assets:
Property and Equipment	7		247			190
Right-of-Use Assets	9		4,200			3,722
Notes Receivable from IN Nevada Shareholders	18		5,349			3,264
Goodwill	4		18,154			–
Intangible Assets	11		87			87
Other Non-Current Assets			255			165
Deferred Tax Asset	20		2,065			2,650
Total Non-Current Assets			30,357			10,078

TOTAL ASSETS		$	71,527		$	47,219

LIABILITIES
Current Liabilities:
Trade and Other Payables	10	$	15,767		$	13,310
Reserve for Returns			491			814
Lease Liability – Current	9		2,110			1,366
Line of Credit	8		10,209			6,178
Total Current Liabilities			28,577			21,668

Non-Current Liabilities:
Lease Liability – Non Current	9		2,182			2,434
Note Payable – Non Current	14		489			–
Contingent Consideration	4		8,908			–
Deferred Tax Liability	20		871			1
Total Non-Current Liabilities			12,450			2,435

TOTAL LIABILITIES		$	41,027		$	24,103

EQUITY
Subordinate Voting Shares	12		3,689			3,000
Proportionate Voting Shares	12		5,610			–
Multiple Voting Shares	12		59			59
Class B Non Voting Shares	12		13,750			13,750
Accumulated Other Comprehensive Income			(33	)		(11	)
Retained Earnings			855			189
Total Controlling Interest			23,930			16,987
Non-Controlling Interest of IN Nevada	19		6,570			6,129
Total Equity			30,500			23,116
TOTAL LIABILITIES & EQUITY		$	71,527		$	47,219

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Profit and Comprehensive Income

	For the Three Months Ended						For the Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
		2022			2021			2022			2021
Operating Revenue	$	22,024		$	23,673		$	66,427		$	74,401
Cost of Sales		(11,421	)		(13,556	)		(35,219	)		(40,431	)
Gross Profit		10,603			10,117			31,208			33,970

Operating Expenses:
Selling, General and Administrative Expenses		9,981			8,885			27,555			25,800
Income from Operations		622			1,232			3,653			8,170

Other Expense:
Interest Expense		(181	)		(34	)		(541	)		(91	)
Listing Expense		–			(2,502	)		–			(2,502	)
Total Other Income / (Expense)		(181	)		(2,536	)		(541	)		(2,593	)

Profit / (Loss) before Income Taxes		441			(1,304	)		3,112			5,577

Income Tax Expense (Note 20)		(1,024	)		(162	)		(2,003	)		(351	)

Net Profit / (Loss)		(583	)		(1,466	)		1,109			5,226
Less: Net Profit / (Loss) Attributable to
Non-Controlling Interest of IN Nevada		(90	)		(142	)		(441	)		–
Net Profit / (Loss) Attributable to Controlling Interest	$	(673	)	$	(1,608	)	$	668		$	5,226

Foreign Currency Translation Differences		(33	)		39			(45	)		39

Total Comprehensive Income / (Loss)		(616	)		(1,427	)		1,064			5,265
Less: Comprehensive Income / (Loss) Attributable to
Non-Controlling Interest of IN Nevada		(90	)		(142	)		(441	)		611
Comprehensive Income / (Loss) Attributable to Controlling Interest	$	(706	)	$	(1,569	)	$	623		$	5,876

Earnings per share – basic	$	(0.39	)	$	(1.22	)	$	0.73		$	4.35
Earnings per share – diluted	$	(0.00	)	$	(0.00	)	$	0.00		$	0.02
Weighted average number of shares outstanding – basic		1,509,516			1,200,001			1,509,547			1,200,001
Weighted average number of shares outstanding – diluted		323,529,359			312,218,241			322,483,202			312,218,241

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Cash Flows

	For the Nine Months Ended
	September 30,			September 30,
	2022			2021

Net Profit	$	1,109		$	5,265
Adjustments to Reconcile Net Profit to Net Cash Provided by Operating Activities:
Depreciation and Amortization		2,230			1,061
Change in Allowance for Doubtful Accounts		11			97
Change in Inventory Reserve		(3,766	)		–
Deferred Tax Asset		585			–
Non-Cash Share Capital from Share-Based Payment Transaction		–			3,012
Non-Cash Share Capital from Acquisitions		(689	)		–
Interest Income		–			–
Interest Expense		499			92
Income Taxes Expense		1,424			351
Changes in Working Capital:
Trade Receivables		981			3,526
Inventory		(1,130	)		(1,731	)
Prepaid Expenses and Other Assets		(713	)		615
Trade and Other Payables		3,475			2,320
Reserve for Returns		(323	)		(7	)
Changes in Other Non-Current Assets		(90	)		(29	)
Net Cash Provided by Operating Activities		3,603			14,572

Cash Flow from Investing Activities:
Purchase of Investments		–			(1	)
Purchase of Property and Equipment		(142	)		(47	)
Contingent Consideration		8,908			–
Goodwill		(18,154	)		–
Net Cash Used in Investing Activities		(9,388	)		(48	)

Cash Flow from Financing Activities:
Proceeds from Line of Credit		686			18,614
Payments on Line of Credit		6,863			(23,924	)
Notes Receivable from Related Parties		(2,085	)		–
Distributions to Shareholders		–			(8,021	)
Payments on Lease Liability		955			(991	)
Net Cash Used in Financing Activities		6,419			(14,322	)
Effect of Foreign Exchange on Cash		(54	)		–
Net Increase in Cash		580			202
Cash at Beginning of the Period		625			442
Cash at End of the Period	$	1,205		$	644

_____________________
¹ Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.
² Based on a Company survey with a sample size of 500 randomly selected adults.

Irwin Naturals Files Q3 2022 Financials

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice